Literature DB >> 15917540

Effects of a high-fat meal on the relative oral bioavailability of piperaquine.

Ing-Kye Sim1, Timothy M E Davis, Kenneth F Ilett.   

Abstract

Piperaquine (PQ) is an antimalarial drug whose high lipid solubility suggests that its absorption can be increased by a high-fat meal. We examined the pharmacokinetics of PQ phosphate (500 mg given orally) in the fasting state and after a high-fat meal in eight healthy Caucasian volunteers (randomized crossover). Plasma PQ concentration-time profiles were analyzed by using noncompartmental pharmacokinetic analysis. In the fed state, the geometric mean Cmax increased by 213%, from 21.0 to 65.8 microg/liter (P<0.001). The time of Cmax was not significantly different between the fasting and fed states. The geometric mean area under the concentration-time curve from zero onward (AUC0-infinity) increased by 98%, from 3,724 to 7,362 microg h/liter (P=0.006). The oral bioavailability of PQ relative to the fasting state was 121% greater after the high-fat meal (95% confidence interval, 26 to 216% increase; P=0.020). The side effects, postural blood pressure changes, electrocardiographic corrected QT interval, serum glucose, and other biochemical and hematological indices were similar in the fasting and fed states over 28 days of follow-up.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917540      PMCID: PMC1140540          DOI: 10.1128/AAC.49.6.2407-2411.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Piperaquine: a resurgent antimalarial drug.

Authors:  Timothy M E Davis; Te-Yu Hung; Ing-Kye Sim; Harin A Karunajeewa; Kenneth F Ilett
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Food increases the bioavailability of mefloquine.

Authors:  C Crevoisier; J Handschin; J Barré; D Roumenov; C Kleinbloesem
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 4.  Antimalarial drugs and glucose metabolism.

Authors:  T M Davis
Journal:  Br J Clin Pharmacol       Date:  1997-07       Impact factor: 4.335

5.  Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection.

Authors:  Te-Yu Hung; Timothy M E Davis; Kenneth F Ilett
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-07-05       Impact factor: 3.205

6.  Examination of some factors responsible for a food-induced increase in absorption of atovaquone.

Authors:  P E Rolan; A J Mercer; B C Weatherley; T Holdich; H Meire; R W Peck; G Ridout; J Posner
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 7.  Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria.

Authors:  J Karbwang; K Na-Bangchang
Journal:  Fundam Clin Pharmacol       Date:  1994       Impact factor: 2.748

8.  Recent studies on antimalarial efficacy of piperaquine and hydroxypiperaquine.

Authors:  L Chen
Journal:  Chin Med J (Engl)       Date:  1991-02       Impact factor: 2.628

9.  Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea.

Authors:  Harin A Karunajeewa; Adedayo Kemiki; Michael P Alpers; Kerry Lorry; Kevin T Batty; Kenneth F Ilett; Timothy M Davis
Journal:  Pediatr Infect Dis J       Date:  2003-03       Impact factor: 2.129

10.  [Comparative study of artemisinin suppositories and piperaquine phosphate in the treatment of falciparum malaria].

Authors:  X B Guo; L C Fu
Journal:  Zhong Xi Yi Jie He Za Zhi       Date:  1989-08
View more
  45 in total

1.  Role of P glycoprotein in absorption of novel antimalarial drugs.

Authors:  Andrew Crowe; Kenneth F Ilett; Harin A Karunajeewa; Kevin T Batty; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2006-08-17       Impact factor: 5.191

2.  Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.

Authors:  Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Sommethy Sok; Winita Ta-Aksorn; Chanikarn Kodchakorn; Sut-Thang Pann; Soklyda Chann; Mali Ittiverakul; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mary So; Theng Youdaline; Erin Milner; Mariusz Wojnarski; Charlotte Lanteri; Jessica Manning; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.

Authors:  Marcus J Rijken; Rose McGready; Aung Phae Phyo; Niklas Lindegardh; Joel Tarning; Natthapon Laochan; Hla Hla Than; Oh Mu; Aye Kyi Win; Pratap Singhasivanon; Nicholas White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

4.  Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.

Authors:  Sam Salman; Madhu Page-Sharp; Kevin T Batty; Kaye Kose; Susan Griffin; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

5.  Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.

Authors:  Jessica Manning; Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Mary So; Darapiseth Sea; Youry Se; Sok Somethy; Sut-Thang Phann; Soklyda Chann; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mashamon Mitprasat; Raveewan Siripokasupkul; Paktiya Teja-Isavadharm; Eugene Soh; Ans Timmermans; Charlotte Lanteri; Jaranit Kaewkungwal; Montida Auayporn; Douglas Tang; Char Meng Chour; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

6.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.

Authors:  Brioni R Moore; Kevin T Batty; Christopher Andrzejewski; Jeffrey D Jago; Madhu Page-Sharp; Kenneth F Ilett
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

8.  Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.

Authors:  Darren J Creek; Victor Bigira; Shelley McCormack; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan W Tappero; Taylor G Sandison; Niklas Lindegardh; Francois Nosten; Francesca T Aweeka; Sunil Parikh
Journal:  J Infect Dis       Date:  2013-02-27       Impact factor: 5.226

9.  Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects.

Authors:  Nguyen Trong Chinh; Nguyen Ngoc Quang; Nguyen Xuan Thanh; Bui Dai; Jason P Geue; Russell S Addison; Thomas Travers; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

10.  Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.

Authors:  Quique Bassat; Modest Mulenga; Halidou Tinto; Patrice Piola; Steffen Borrmann; Clara Menéndez; Michael Nambozi; Innocent Valéa; Carolyn Nabasumba; Philip Sasi; Antonella Bacchieri; Marco Corsi; David Ubben; Ambrose Talisuna; Umberto D'Alessandro
Journal:  PLoS One       Date:  2009-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.